Speakers

Expand/Collapse

Charles Cheung
Senior Scientist
Abbvie

Day Two

Thursday 24 September, 2020

9:25 am | RSL-DVDs: An Improved Disulfide-Reinforced Single Linker DVD-Ig Bispecific Format

Paul Widboom
Associate Director
Adimab LLC

Pre-Conference Focus Day

12:15 pm | Discovering the Balance Between Safety & Efficacy

Jonathan Lai
Associate Professor - Biochemistry
Albert Einstein College of Medicine

Peter Ellmark
VP Discovery
Alligator Bioscience AB

Matthew Chun
Scientist
Amgen

John Delaney
Executive Director - Research
Amgen Inc.

Ryan Potts
Cell & Molecular Biology, Associate Member, St. Jude Faculty
Amgen/St Jude Children’s Research Center

Day Two

Thursday 24 September, 2020

3:05 pm | Small Molecule Bispecifics for Targeted Protein Degradation

Jane Gross
Chief Scientific Officer
Aptevo Therapeutics Inc.

Pre-Conference Focus Day

11:05 am | Panel Discussion: Evaluating the Criteria Essential to Success in the Increasingly Competitive CD3 Bispecific Field

Alison Betts
Senior Director of Scientific Collaborations, Fellow of Modeling & Simulation Applied
Applied Biomath

Day One

Wednesday 23 September, 2020

3:05 pm |

Changshou Gao
Senior Director and Fellow (R&D)
AstraZeneca

Day One

Wednesday 23 September, 2020

9:25 am | Panel Discussion: Solving the Specificity Problem to Pioneer Bispecifics in Solid Tumor Indications

Amrik Basran
Chief Scientific Officer
Avacta Group Plc

Day Two

Thursday 24 September, 2020

9:00 am | Affimer Therapeutics: A Versatile Antibody Mimetic Platform for the Generation of Bispecific Immunotherapies

Rebecca Williams
Senior Analyst
Beacon

Day One

Wednesday 23 September, 2020

9:00 am | Review of the Bispecific Landscape

Eugene Zhukovsky
Chief Scientific Officer - Research
Biomunex Pharmaceuticals

Day Two

Thursday 24 September, 2020

3:30 pm | Panel Discussion: Examining Trends & Future Opportunities in this Rapidly Evolving Space - What Does the Future of the BioSpecific Look Like?

9:50 am | Panel Discussion: Demonstrating the Superiority of Bispecifics in Immuno-Oncology Indications in Comparison with Antibody Combinations

Rakesh Dixit
President & Chief Executive Officer
Bionavigen

Pre-Conference Focus Day

9:00 am | Learning from Successful & Failed Bispecific Biologics

Steven Chamow
President
Chamow & Associates Inc.

Pre-Conference Focus Day

3:15 pm | Workshop - The Process of CMO Selection for Bispecific Antibody Development: Matching Capabilities to Need

Ambrose Williams
Scientist, Tech Dev
Genentech

Stephanie Truhlar
Senior Research Advisor, AME/Biotechnology Discovery Research
Eli Lilly and Company

Day One

Wednesday 23 September, 2020

2:10 pm | Methods for Obtaining Manufacturable IgG Bispecific Antibodies

Vittal Shivva
Scientist
Genentech

Jonah Rainey
Vice President - Cell Biology & Immunology
Gritstone Oncology

Day One

Wednesday 23 September, 2020

3:05 pm |

Rick Austin
Senior Director
Harpoon Therapeutics Inc.

Pre-Conference Focus Day

1:35 pm | TriTACs Are T-cell Engaging Drugs for Treatment of Solid Tumors

Horacio Nastri
Executive Director
Incyte Corporation

Day Two

Thursday 24 September, 2020

9:50 am | Panel Discussion: Demonstrating the Superiority of Bispecifics in Immuno-Oncology Indications in Comparison with Antibody Combinations

Pre-Conference Focus Day

9:25 am | Panel Discussion: Contrasting Bispecific Therapeutics & CAR-T Approaches

Indrajeet Singh
Principal Scientist
Johnson & Johnson

Paul Moore
Vice President - Cell Biology & Immunology
MacroGenics

Chad May
Senior Vice President - Research & Development
Maverick Therapeutics

Day Two

Thursday 24 September, 2020

1:45 pm | Protease Dependent COBRA™ Activity Regresses Established Solid Tumors in Mice

Kalyan Pande
Associate Principal Scientist, Biologics Discovery
Merck & Co

Pieter Fokko van Loo
Chief Scientific Officer and Executive Vice President,
Merus NV

Day Two

Thursday 24 September, 2020

4:15 pm | Triclonics™ Engagers: Multi-specific Common Light Chain Antibodies Discovered by Unbiased Functional Screening

Niina Veitonmaki
Director - In Vivo Immune-Oncology & Head of in Vivo Core
Molecular Partners AG

Day Two

Thursday 24 September, 2020

2:10 pm | Novel Therapeutic Design of Tumor-targeted CD40 Agonistic DARPin® Molecule Leads to Antitumor Activity with Limited Systemic Toxicity

Nimish Gera
Head of Biologics
Mythic Therapeutics

John Blankenship
Senior Investigator & Group Leader - Antibody Discovery
Novartis

Day One

Wednesday 23 September, 2020

9:25 am | Panel Discussion: Solving the Specificity Problem to Pioneer Bispecifics in Solid Tumor Indications

Day Two

Thursday 24 September, 2020

3:30 pm | Panel Discussion: Examining Trends & Future Opportunities in this Rapidly Evolving Space - What Does the Future of the BioSpecific Look Like?

Gosia Nocula-Lugowska
Senior Principal Scientist - Antibody Discovery and Engineering
Pfizer

Pre-Conference Focus Day

1:55 pm | Discovery & Optimization of T-cell Bispecifics for the Treatment of Solid Tumors

Mohamed Elmeliegy
Associate Director - Clinical Pharmacology
Pfizer

Pre-Conference Focus Day

11:05 am | Panel Discussion: Evaluating the Criteria Essential to Success in the Increasingly Competitive CD3 Bispecific Field

11:50 am | An Industry Perspective on CD3 Bispecifics Starting Doses & Efficacious Dose Projections

Kara Olson
Senior Staff Scientist
Regeneron Pharmaceuticals

Day One

Wednesday 23 September, 2020

9:50 am | Development of Novel Fully Human Bispecific Antibodies for Oncology

Aynur Hermann
Director, Therapeutic Proteins
Regeneron Pharmaceuticals

Jasmin Sydow-Andersen
Senior Scientist / Lab Head Mass Spectrometry
Roche

Fateme Tousi
Scientist
Sanofi

Wei Yan
Yan President & CEO
Sound Biologics

Nathan Trinklein
Chief Technology Officer
TeneoBio

Rastislav Tamaskovic
Researcher
University Medical Center Groningen

Andrew Tsourkas
Professor of Bioengineering
University of Pennsylvania

Jeffrey Way
Senior Staff Scientist
Wyss Institute at Harvard University

John Burke
Co-Founder, President and CEO
Applied Biomath

Jonathan Davis
Head, Innovation
Invenra Inc.

Arthur Chirino
Senior Director, Product Control Strategy & Manufacturing
Xencor

John Desjarlais
Chief Scientific Officer
Xencor

Day One

Wednesday 23 September, 2020

3:05 pm |

Rupert Davies
Director, Pharmacokinetics
Zymeworks